Have you ever torn a:

• muscle
• rotator cuff
• meniscus
• cartilage

How about someone you know? Or a favourite athlete?

We wouldn’t blame you if you thought the care and repair of these kinds of injuries is pretty standard and highly successful …. but you would be wrong.  There is a MASSIVE problem with surgery failure rates for each of these as follows:

• Rotator Cuff   50-60%
• Meniscus         20-40%
• Cartilage         15-35%

$ORTH believes it has found the solution to this multi-billion dollar problem thanks to its proprietary RESTORE technology platform which dramatically improves the success rate of orthopedic and sports medicine surgeries.

In short, the technology uses biologics derived from things like plasma and bone marrow concentrate to regenerate new tissue in various musculoskeletal conditions.  This includes Wound Healing, Cartilage repair and Osteo-arthritis

In layman’s terms, it means $ORTH has a wonder delivery platform that delivers biologics – drugs made from biological processes – to repair soft tissues in the human body.

Newly appointed CEO Philippe Deschamps States “I Know We Are In The Lead” For FDA Trials Into The Healing Of Tendons, Ligaments, Cartilage and Meniscus .. and he has plenty of reason to carry such confidence considering the following …

3RD PARTY VALIDATION -$ORTH AGREEMENT WITH A GLOBAL STRATEGIC MEDICAL COMPANY FOR ITS ROTATOR CUFF TEAR REPAIR PHASE I/II U.S. CLINICAL TRIAL

On February 7th, $ORTH announced it entered into a Material Transfer Agreement ("MTA") with an undisclosed, industry-leading, global strategic medical company for the exclusive use of their proprietary platelet-rich plasma ("PRP") system in Ortho's upcoming ORTHO-R rotator cuff tear ("RCT") repair, phase I/II U.S. clinical trial.

The Strategic Company will provide the PRP system disposable kits for all enrolled patients in the study as well as technical and training support. $ORTH, in return, has provided the Strategic Company with a right of "first offer" to distribute ORTHO-R in combination with their proprietary PRP System.

KEY U.S. COMPOSITION AND METHOD PATENT FOR ORTHO-R SOFT TISSUE REPAIR PLATFORM

The company recently announced the receipt of Key U.S composition and method patent for ORTHO-R Soft tissue repair platform.

Why is this important?

• New patent issued by U.S. Patent and Trademark Office protects core IP until 2035
• Positions Company as leading player in the dynamic regenerative medicine market
• Enables delivery of PRP in soft tissue repair surgery in a proprietary way 

What did CEO Philippe Deschamps have to say?

"This US patent is a critical step in protecting our technology platform in the world's largest orthopedic soft tissue repair market and provides further validation of our novel and unique approach to soft tissue repair regenerative technologies. Receiving this patent from the USPTO is a key, hard fought, value creation milestone for the company. This important patent is added to our growing intellectual property portfolio and the 9 other patents already issued in major markets around the world".

$ORTH IS ATTACKING AND IN THE LEAD OF A MULTI BILLION $$ OPPORTUNITY

In terms of Soft Tissue Repair this is a massive market opportunity as follows:

ROTATOR CUFF TEAR – SHOULDER DYSFUNCTION AND PAIN

• 4m patients in the U.S. alone
• 600,000 annual surgeries in the U.S. alone
• $600m+ market opportunity

MENISCUS TEAR – PAINFUL AND COMPROMISES KNEE FUNCTION

• 1.2m surgeries annually in U.S. alone
• $1bn+ market opportunity

CARTILAGE LESIONS REPAIR – LESIONS CAUSE FRICTION AND PAIN

• 1.2m detected lesions annually in U.S. alone
• 120,000 surgeries and a lack of options
•  $1bn+ market opportunity

Watch this powerful interview with CEO Philippe Deschamps